Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

AVEO PHARMACEUTICALS, INC.

(AVEO)
  Report
Delayed Nasdaq  -  04:00 2022-12-05 pm EST
14.91 USD   -0.07%
12/02Aveo Pharmaceuticals : Merger Agreement - Form 8-K
PU
12/02Aveo Pharmaceuticals, Inc. : Other Events (form 8-K)
AQ
11/09North American Morning Briefing: Midterm Outcome -3-
DJ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/29/2022 11/30/2022 12/01/2022 12/02/2022 12/05/2022 Date
14.87(c) 14.95(c) 14.93(c) 14.92(c) 14.91(c) Last
330 046 1 210 251 605 988 335 307 246 266 Volume
+0.07% +0.54% -0.13% -0.07% -0.07% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 112 M - -
Net income 2022 -23,7 M - -
Net Debt 2022 - - -
P/E ratio 2022 -21,8x
Yield 2022 -
Sales 2023 176 M - -
Net income 2023 19,2 M - -
Net Debt 2023 - - -
P/E ratio 2023 31,1x
Yield 2023 -
Capitalization 519 M 519 M -
Capi. / Sales 2022 4,63x
Capi. / Sales 2023 2,94x
Nbr of Employees 114
Free-Float 99,8%
More Financials
Company
AVEO Pharmaceuticals, Inc. is an oncology-focused biopharmaceutical company. The Company is focused on delivering medicines for patients with cancer. The CompanyÔÇÖs commercial product include FOTIVDA (tivozanib), which is an oral, vascular endothelial growth factor receptor (VEGFR) and tyrosine kinase inhibitor (TKI). The Company markets FOTIVDA (tivozanib) in the United States for the treatment of adult patients... 
Sector
Pharmaceuticals
Calendar
01/05Shareholder meeting
More about the company
Ratings of AVEO Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about AVEO PHARMACEUTICALS, INC.
12/02Aveo Pharmaceuticals : Merger Agreement - Form 8-K
PU
12/02Aveo Pharmaceuticals, Inc. : Other Events (form 8-K)
AQ
11/09North American Morning Briefing: Midterm Outcome -3-
DJ
11/08Stifel Downgrades AVEO Pharmaceuticals to Hold From Buy, Price Target is $15
MT
11/07Aveo : Q3 Earnings Snapshot
AQ
11/07AVEO PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Condition..
AQ
11/07Earnings Flash (AVEO) AVEO PHARMACEUTICALS Reports Q3 Revenue $30.4M, vs. Street Est of..
MT
11/07AVEO Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Mont..
CI
11/07AVEO Oncology Reports Third Quarter 2022 Financial Results
AQ
11/07Aveo Pharmaceuticals, Inc. Withdraws Earnings Guidance for the Year 2022
CI
10/31JonesTrading Downgrades AVEO Pharmaceuticals to Hold From Buy With $15 Price Target
MT
10/26Actinium Pharmaceuticals' Q4 Phase 3 Trial Updates Could Make Expected Milestones 2023 ..
AQ
10/24SVB Securities Downgrades AVEO Pharmaceuticals to Market Perform From Outperform, Retai..
MT
10/24Actinium Pharmaceuticals' Investor Update Puts Clinical Milestones And Potential Cataly..
AQ
10/19South Korea's Kospi, Kosdaq Decline Ahead of Earnings Season; LG Chem Sheds 3%
MT
More news
News in other languages on AVEO PHARMACEUTICALS, INC.
11/07AVEO Pharmaceuticals, Inc. annonce ses résultats pour le troisième trimestre et les neu..
11/07Aveo Pharmaceuticals, Inc. retire ses prévisions de bénéfices pour l'année 2022
10/19Le Kospi et le Kosdaq baissent à l'approche de la saison des bénéfices ; LG Chem perd 3..
10/19LG Chem va acquérir AVEO Pharmaceuticals pour 566 millions de dollars
10/19MÄRKTE ASIEN/China-Börsen schwach - Parteitag der KP enttäuscht
More news
Analyst Recommendations on AVEO PHARMACEUTICALS, INC.
More recommendations
ETFs positioned on AVEO PHARMACEUTICALS, INC.ETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
IShares Micro-Cap ETF - USD0.05%1.43%United_States
More ETFs positioned on AVEO PHARMACEUTICALS, INC.
Chart AVEO PHARMACEUTICALS, INC.
Duration : Period :
AVEO Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AVEO PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Last Close Price 14,91 $
Average target price 15,00 $
Spread / Average Target 0,60%
EPS Revisions
Managers and Directors
Michael P. Bailey President, Chief Executive Officer & Director
Erick J. Lucera Chief Financial Officer
Kenneth M. Bate Chairman
Matthew Coulter Vice President-Information Technology
Jebediah Ledell Chief Operating Officer
Sector and Competitors